Navigation Links
Chimerix Appoints Two New Vice Presidents to Clinical Management Team
Date:7/21/2010

RESEARCH TRIANGLE PARK, N.C., July 21 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that it has expanded its clinical management team with the appointment of Timothy King, MSPH, as Vice President of Clinical Operations and Herve Mommeja-Marin, MD, as Vice President of Clinical Research.  

In these new roles, Mr. King will oversee clinical operations and site management for Chimerix and Dr. Mommeja-Marin will oversee clinical strategy and study design.  Both individuals will report to Wendy Painter, MD, Chief Medical Officer.  

"Tim King and Herve Mommeja-Marin bring to Chimerix a wealth of talent and knowledge within infectious diseases which will be of great value as we advance of our antiviral clinical development programs," said Kenneth I. Moch, President and CEO. "We anticipate significant progress in our two clinical stage programs - CMX001 against double-stranded DNA viruses and CMX157 against HIV - and look forward to working with Tim and Herve as we develop these assets."

Mr. King has over 20 years of global experience managing and directing device and drug development clinical trials.  Most recently he served as a Group Director at Quintiles, where he had responsibility for more than 20 Phase I to IV trials in over 40 countries for a wide range of drugs, biologics, devices and diagnostics. Mr. King's prior experience includes serving as the Head of Clinical Operations for Infectious Diseases, Hepatology, Vaccines, and Transplants at Duke Clinical Research Institute, where he oversaw programs in cytomegalovirus, hepatitis, and HIV.  Mr. King holds a masters degree in epidemiology from the University of North Carolina.  

Dr. Mommeja-Marin brings to Chimerix over 20 years of global medical and clinical research experience in infectious and respiratory disease and clinical medicine.  Most recently he was Senior Medical Director, Infectious Diseases, for i3 Research, a contract research organization, where he was the lead therapeutic expert in infectious diseases.  His background includes numerous Phase I through Phase IV clinical trials, including more than 25 late-stage trials. Previously, Dr. Mommeja-Marin was Director of Clinical Research for Gilead Sciences, Inc., where he was responsible for the global development of hepatitis B and hepatitis C programs. He also held the positions of Clinical Research Physician at Triangle Pharmaceuticals and Physician of Internal Medicine and Infectious Diseases at Assistance Publique- Hopitaux de Paris in France. Dr. Mommeja-Marin received a medical degree from Paris VII University, France.  He is certified in internal medicine and multiple subspecialties.

About Chimerix

Chimerix is developing antiviral therapeutics to treat life-threatening diseases.  Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, adenovirus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza.  The company's lead compound, CMX001, is in Phase 1 and Phase 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients.  CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release.  Chimerix has advanced a second antiviral compound, CMX157, into Phase 1 clinical studies.  CMX157 is being developed as a potential once-weekly nucleoside analogue against HIV infections.  Building on the company's extensive chemical library, Chimerix is also pursuing translational medicine efforts to address malaria, dengue fever and other public health needs.  Chimerix has received financing from leading venture capital firms, including Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, as well as significant funding from the National Institute of Allergy and Infectious Diseases.  Additional information about Chimerix and its antiviral drug development programs may be found online at http://www.chimerix.com.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chimerix to Present at Upcoming Investor Conferences
2. Chimerix Initiates Phase 1 Study of CMX157
3. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
4. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
5. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
6. Chimerix Joins International Network of Organizations to Cure Malaria
7. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
8. SemBioSys Appoints President of US and International Operations and Announces the Appointments of Three Vice Presidents
9. Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer
10. Bacterin International Appoints Three New Members to Its Board of Directors
11. Shire plc Appoints Two New Board Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
(Date:6/23/2016)... June 23, 2016 On Wednesday, June ... 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% ... at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the ... Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. ... BIND ). Learn more about these stocks by ...
(Date:6/23/2016)... 2016  Amgen (NASDAQ: AMGN ) today ... life sciences incubator to accelerate the development of ... space at QB3@953 was created to help high-potential life ... many early stage organizations - access to laboratory infrastructure. ... launched two "Amgen Golden Ticket" awards, providing each winner ...
(Date:6/22/2016)... , June 22, 2016  According to Kalorama ... generation sequencing (NGS) market include significant efforts in ... sequencers.  More accessible and affordable sequencers, say the ... demand for consumables including sample prep materials.  The ... for Sample Preparation for Next Generation Sequencing (NGS) ...
Breaking Biology Technology:
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
Breaking Biology News(10 mins):